Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

Stage IV Breast Cancer Clinical Trial

Official title:

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Patients With Stage Ⅳ Breast Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04199520
• Other study ID #: HNCH-BC003
• Status: Withdrawn
• Phase: Phase 2
• Start date: April 15, 2020
• Est. completion date: May 1, 2022

Study information

• Verified date: December 2019
• Source: Henan Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effect of primary resection combined with systemic therapy and pure systemic therapy on the overall survival of patients with stage Ⅳ breast cancer.

Description:

In developing countries, the proportion of breast cancer patients who have a stage IV diagnosis at the first diagnosis can be as high as 25%. For advanced breast cancer, previous views have suggested that surgery as one of the palliative treatments does not improve patient survival. The proportion of patients undergoing surgery for stage IV breast cancer has gradually decreased over the past 30 years. At present, there is still no clear recommendation and guidance in common clinical guidelines for the primary surgery for stage IV breast cancer. Some retrospective studies suggest that surgery can improve the survival of advanced breast cancer, but the results of prospective studies are inconclusive, and surgery is still not a routine choice for stage IV breast cancer.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 1, 2022
• Est. primary completion date: May 1, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• • Sign the informed consent

• ages 18-70, female;

• Breast cancer meets the following criteria:

• Histologically diagnosed invasive breast cancer, measure distant metastases with local standard assessment methods;

• Known hormone receptors and HER-2 status (ER, PR and HER2);

• Eastern Cooperative Oncology Group (ECOG) performance status score =1;

• Estimated patient survival beyond 1 year;

• The time from diagnosis or systemic treatment to randomization does not exceed 1 year;

• According to RECIST 1.1, patients receiving chemotherapy or endocrine therapy are effective, including complete remission, partial remission, or stabilization. If the patient only receives endocrine therapy, the time is not less than 6 months; when receiving chemotherapy, the number of cycles is not less than 4 cycles;

• HER2-positive patients: the proportion of patients receiving targeted therapy is not less than 80% of the total HER2-positive patients;

• Patients had no obvious surgical contraindications before randomization;

• Researchers judge that they can comply with the research protocol

Exclusion Criteria:

• • Double breast cancer;

• Progression of metastases after systemic treatment;

• Poorly controlled brain metastases, liver metastases and multiple metastases;

• History of local breast radiotherapy after diagnosis;

• Have a history of other malignancies within 5 years prior to screening, with cervical cancer in situ treated properly except for non-melanoma skin cancer or stage I uterine cancer;

• Have undergone a major breast cancer-free surgical procedure within 4 weeks before randomization, or the patient has not fully recovered from such a surgical procedure;

• Have severe comorbidities or other comorbid conditions that interfere with planned treatment, or any other condition in which the investigator does not consider the patient suitable for participation in the study.

• Patients can withdraw informed consent at any time;

• pregnancy;

• The sponsor has determined that a major protocol violation that could compromise patient safety;

• Patients' non-compliance with protocol requirements on multiple occasions;

• The investigator believes that withdrawal from the trial will be of greatest benefit to the patient.

Related Conditions & MeSH terms

• Breast Neoplasms
• Stage IV Breast Cancer

Intervention

Combination Product:
• surgery combined with systemic therapy
surgery combined with systemic therapy

Other:
• systemic therapy
systemic therapy

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS	The time from diagnosis to death	up to 2 year
Secondary	PFS	The time from randomization to disease progression or death, including local PFS and distant PFS Local PFS refers to the time from randomization of patients to local or regional lymph node recurrence in the surgical group or local or regional lymph node progression in the non-surgical group. distant PFS refers to the time from randomization of a patient to local or distant distant disease progression or death.	up to 2 year
Secondary	BCSS (Breast Cancer Specific Survival)	The time from the random start of a patient to death due to breast cancer, excluding deaths caused by other causes	up to 2 year